Keystone Financial Group Inc. Takes Position in Johnson & Johnson (NYSE:JNJ)

Keystone Financial Group Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,311 shares of the company’s stock, valued at approximately $334,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Johnson & Johnson by 2.0% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 510,884 shares of the company’s stock valued at $73,884,000 after buying an additional 9,913 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Johnson & Johnson by 8.1% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,281 shares of the company’s stock valued at $330,000 after acquiring an additional 171 shares in the last quarter. Guardian Wealth Advisors LLC grew its holdings in Johnson & Johnson by 2.9% in the fourth quarter. Guardian Wealth Advisors LLC now owns 5,899 shares of the company’s stock worth $853,000 after purchasing an additional 167 shares during the last quarter. Strategic Financial Concepts LLC increased its position in shares of Johnson & Johnson by 14,102.0% during the fourth quarter. Strategic Financial Concepts LLC now owns 311,876 shares of the company’s stock worth $45,104,000 after purchasing an additional 309,680 shares in the last quarter. Finally, Iron Horse Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 33.2% during the 4th quarter. Iron Horse Wealth Management LLC now owns 3,296 shares of the company’s stock valued at $477,000 after purchasing an additional 822 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3 %

Johnson & Johnson stock opened at $153.10 on Monday. The firm has a market cap of $368.61 billion, a PE ratio of 23.02, a P/E/G ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock’s 50 day simple moving average is $147.42 and its two-hundred day simple moving average is $156.08. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $2.29 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on JNJ shares. Guggenheim upped their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Raymond James decreased their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.